Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
53
SYRE Quote, Financials, Valuation and Earnings
Last price:
$35.13
Seasonality move
:
-3.15%
Day range:
$33.16 - $35.21
52-week range:
$10.91 - $35.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
701.12x
P/B ratio:
5.99x
Volume:
790.5K
Avg. volume:
575.8K
1-year change:
47.19%
Market cap:
$2.7B
Revenue:
--
EPS (TTM):
-$2.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.80 | 315.28% | -13.4% | $56.43 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.11 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$834.6M | $0.71 | 11.96% | 37.26% | $90.74 |
|
PTCT
PTC Therapeutics, Inc.
|
$281.5M | -$0.43 | -78.99% | -50.2% | $88.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
$35.12 | $56.43 | $2.7B | -- | $0.00 | 0% | 701.12x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.11 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$58.13 | $90.74 | $11.2B | 21.78x | $0.00 | 0% | 3.68x |
|
PTCT
PTC Therapeutics, Inc.
|
$74.68 | $88.50 | $6B | 8.73x | $0.00 | 0% | 3.45x |
|
SVRA
Savara, Inc.
|
$5.30 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 1.781 | -- | 10.51x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
PTCT
PTC Therapeutics, Inc.
|
161.23% | 0.479 | 8.36% | 2.20x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$56.9M | -28.51% | -28.51% | -- | -$37.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
PTCT
PTC Therapeutics, Inc.
|
$187.7M | $3.5M | -382.54% | -- | 1.65% | -$322.5M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Spyre Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SYRE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 25.76%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SYRE or ACAD?
Spyre Therapeutics, Inc. has a consensus price target of $56.43, signalling upside risk potential of 60.67%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.11 which suggests that it could grow by 32.03%. Given that Spyre Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SYRE or ACAD More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SYRE or ACAD?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or ACAD?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns SYRE or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 20.1%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About SYRE or ALNY?
Spyre Therapeutics, Inc. has a consensus price target of $56.43, signalling upside risk potential of 60.67%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Spyre Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is SYRE or ALNY More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock SYRE or ALNY?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or ALNY?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns SYRE or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -3.91%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About SYRE or BMRN?
Spyre Therapeutics, Inc. has a consensus price target of $56.43, signalling upside risk potential of 60.67%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $90.74 which suggests that it could grow by 56.1%. Given that Spyre Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is SYRE or BMRN More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock SYRE or BMRN?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or BMRN?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Spyre Therapeutics, Inc.'s net income of -$11.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.68x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M BMRNBioMarin Pharmaceutical, Inc.3.68x 21.78x $786.8M -$30.7M
-
Which has Higher Returns SYRE or PTCT?
PTC Therapeutics, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 7.53%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M -
What do Analysts Say About SYRE or PTCT?
Spyre Therapeutics, Inc. has a consensus price target of $56.43, signalling upside risk potential of 60.67%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $88.50 which suggests that it could grow by 18.51%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 PTCTPTC Therapeutics, Inc.7 4 1 -
Is SYRE or PTCT More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.641%.
-
Which is a Better Dividend Stock SYRE or PTCT?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or PTCT?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 8.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.45x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M PTCTPTC Therapeutics, Inc.3.45x 8.73x $211M $15.9M
-
Which has Higher Returns SYRE or SVRA?
Savara, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SYRE or SVRA?
Spyre Therapeutics, Inc. has a consensus price target of $56.43, signalling upside risk potential of 60.67%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 104.01%. Given that Savara, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Savara, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 SVRASavara, Inc.6 0 0 -
Is SYRE or SVRA More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock SYRE or SVRA?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or SVRA?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$11.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
